SCHEMBL13772452

SCHEMBL13772452

CCCCOc1cc(C(N)c2nccnc2Cl)ccc1OCCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.40
CSNK2A1 P68400 2/20 0.37
GLA P06280 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CALM1 P0DP23 1/20 0.36
TNF P01375 1/20 0.36
MAPT P10636 2/20 0.35
HSD17B10 Q99714 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
TSHR P16473 1/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12334942 0.92 L3MBTL1 (0.50) L3MBTL1TNFMAPTPDE4APDE4B
SCHEMBL12335683 0.87 L3MBTL1 (0.37) L3MBTL1GLASMN1; SMN2HSD17B10TSHR
SCHEMBL13772524 0.87 SMPD1 (0.39) L3MBTL1GLASMN1; SMN2BACE1
SCHEMBL12336345 0.86 RAB9A (0.39) L3MBTL1GLASMN1; SMN2MAPTKDM4E
SCHEMBL13772602 0.85 ACHE (0.40) CSNK2A1GLASMN1; SMN2CALM1TNF
SCHEMBL12335696 0.77 TNF (0.53) CALM1TNFPDE4APDE4BPDE4C
SCHEMBL12335177 0.77 ACHE (0.50) TNFMAPTPDE4APDE4BPDE4C
SCHEMBL4154745 0.77 F2 (0.47) L3MBTL1SMN1; SMN2MAPTHSD17B10POLB
SCHEMBL2461700 0.74 NPC1 (0.43) L3MBTL1SMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL13772628 0.74 OPRM1 (0.45) SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 L3MBTL1 3074/4885CSNK2A1 118/4885GLA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.